Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in Narcolepsy Type 1: A Secondary Analysis of a Randomized Clinical Trial.

ABSTRACT:

Importance

Cognitive symptoms negatively impact people with narcolepsy type 1 (NT1). While the effects of orexin receptor 2 (OX2R) agonists have been explored on diagnostic features of the disorder (excessive daytime sleepiness and cataplexy), effects on cognitive symptoms are not characterized.

Objective

To explore the effects of oveporexton, an oral OX2R-selective agonist, on cognition in people with NT1.

Design, setting, and participants

This is a secondary analysis of the TAK-861-2001 phase 2, 8-week, parallel-group, double-blind, placebo-controlled randomized clinical trial, conducted from January 2023 to December 2023, with a 4-week follow-up period. TAK-861-2001 was a multicenter study conducted in clinical settings. Eligible participants were 18 to 70 years of

SUBMITTER: Lammers GJ 

PROVIDER: S-EPMC12687147 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature